|
SREBP2 Inhibitors for Treating T-Cell Acute Lymphoblastic Leukemia
This invention is a method of inhibiting sterol regulatory element-binding protein 2 (SREBP2) in order to treat, prevent, reverse, and/or ameliorate conditions associated with an improper number of hematopoietic stem and progenitor cells (HSPCs). SREBP22 is traditionally known as a transcription factor that plays a role in cholesterol homeostasis. However,...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Qilin Gu
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
